The obligatory requirement for maintaining the B-Raf(V600E)/MEK/MAPK activity in enabling growth arrest of B-Raf(V600E) cancers by MEDICA, may indicate a requirement for hyper-activation of MAPK/Erk by the combined activities of B-Raf(V600E) and MEDICA. This evidence concerns the gene MAP2K7 and cancer.